Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Dextromethorphan is an antitussive with a high margin of safety that has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine. In addition to binding to NMDA receptors, dextromethorphan binds to sigma-1 (σ1) receptors, which are believed to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine whether dextromethorphan elicits antidepressant-like effects and the involvement of σ1 receptors in mediating its antidepressant-like actions. The antidepressant-like effects of dextromethorphan were assessed in male, Swiss Webster mice using the forced swim test. Next, σ1 receptor antagonists (BD1063 and BD1047) were evaluated in conjunction with dextromethorphan to determine the involvement of σ receptors in its antidepressant-like effects. Quinidine, a cytochrome P450 (CYP) 2D6 inhibitor, was also evaluated in conjunction with dextromethorphan to increase the bioavailability of dextromethorphan and reduce exposure to additional metabolites. Finally, saturation binding assays were performed to assess the manner in which dextromethorphan interacts at the σ1 receptor. Our results revealed dextromethorphan displays antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with σ1 receptor antagonists, with BD1063 causing a shift to the right in the dextromethorphan dose response curve. Concomitant administration of quinidine potentiated the antidepressant-like effects of dextromethorphan. Saturation binding assays revealed that a Ki concentration of dextromethorphan reduces both the Kd and the Bmax of [(3)H](+)-pentazocine binding to σ1 receptors. Taken together, these data suggest that dextromethorphan exerts some of its antidepressant actions through σ1 receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [148]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 5×
“Imipramine did not alter locomotor activity, even at doses that produced antidepressant-like effects (Figure 1B; F[2,30] = 0.”
BackgroundResultInfluentialControl of inositol 1,4,5-trisphosphate-induced Ca2+ release by cytosolic Ca2+
Bootman, M. D., Missiaen, L., Parys, J. B., De Smedt, H., & Casteels, R. (1995) · Biochemical Journal · doi:10.1042/bj3060445 · Cited by 5,120
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 3×
“ANOVA confirmed a significant difference between the various treatment groups (F[7,77] = 8.”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“, hallucinations and dissociations) [6,7,8].”
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Depression affects up to one fifth of the world population, stands as the second leading cause of disability worldwide, and imposes a substantial economic burden [1,2].”
BackgroundAssessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 5×
“Consistent with earlier reports that the forced swim test does not reliably detect the effects of SSRIs [37], the SSRI fluoxetine did not significantly reduce immobility time in the forced swim test under the conditions used by our laboratory (F[2,32] = 1.97, n.s.).”
BackgroundResultInfluentialThe ascent of mouse: advances in modelling human depression and anxiety
Cryan, J. F., & Holmes, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1825 · Cited by 1,198 · cited 2×
“, sucrose preference test, novelty suppression) [3,29,30] will be needed in the future to further evaluate the antidepressant potential of dextromethorphan and the involvement of s1 receptors.”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 2×
“ANOVA confirmed a significant difference between the various treatment groups in the antagonism study for dextromethorphan in the forced swim test (F[3,41] = 5.”
ResultPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“3–20 nM) [40,41,42,43], and s1 receptors (343 nM) [44].”
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676 · cited 1×
“3–20 nM) [40,41,42,43], and s1 receptors (343 nM) [44].”
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 1×
“, hallucinations and dissociations) [6,7,8].”
Preclinical models: status of basic research in depression
Nestler, E. J., Gould, E., & Manji, H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01405-1 · Cited by 558 · cited 10×
“In the locomotor studies, BD1047 produced an effect that significantly differed from saline injections (F[3,34] = 6.”
BackgroundResultInfluentialThe sigma-1 receptor chaperone as an inter-organelle signaling modulator
Su, T.-P., Hayashi, T., Maurice, T., Buch, S., & Ruoho, A. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.007 · Cited by 466 · cited 1×
“tions to modulate the activity of various ion channels and signaling molecules, including inositol triphosphates, protein kinases, and calcium [14,15].”
BackgroundCodd, E. E., Shank, R. P., Schupsky, J. J., & Raffa, R. B. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10630-7 · Cited by 388 · cited 2×
“1 mM) [9], but its reported ability to modulate norepinephrine reuptake [38] would be expected to contribute conventional antidepressant effects under clinical conditions.”
BackgroundSchmid, B., Bircher, J., Preisig, R., & Küpfer, A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.235 · Cited by 383 · cited 2×
“In addition, it readily undergoes first-pass metabolism by cytochrome P450 (CYP) 2D6 to its major active metabolite dextrorphan [11].”
BackgroundBinding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349 · cited 1×
“This is consistent with the wider range of protein targets through which imipramine, but not dextromethorphan, interacts, which include: serotonin 5-HT2, muscarinic, and histamine H1 receptors [9,45,46,47,48,49].”
BackgroundThe dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action
Andersen, P. H. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90363-4 · Cited by 346
Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain
Narita, N., Hashimoto, K., Tomitaka, S.-I., & Minabe, Y. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00254-3 · Cited by 254 · cited 1×
“3–20 nM) [40,41,42,43], and s1 receptors (343 nM) [44].”
Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine.
Tran, V. T., Chang, R. S., & Snyder, S. H. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.12.6290 · Cited by 230 · cited 1×
“This is consistent with the wider range of protein targets through which imipramine, but not dextromethorphan, interacts, which include: serotonin 5-HT2, muscarinic, and histamine H1 receptors [9,45,46,47,48,49].”
BackgroundAnimal models of depression in drug discovery: A historical perspective
McArthur, R., & Borsini, F. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.06.005 · Cited by 207 · cited 4×
“, sucrose preference test, novelty suppression) [3,29,30] will be needed in the future to further evaluate the antidepressant potential of dextromethorphan and the involvement of s1 receptors.”
BackgroundInfluentialA new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.
Wong, D. T., Threlkeld, P. G., Best, K. L., & Bymaster, F. P. (1982) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33153-8 · Cited by 194 · cited 2×
“This is consistent with the wider range of protein targets through which imipramine, but not dextromethorphan, interacts, which include: serotonin 5-HT2, muscarinic, and histamine H1 receptors [9,45,46,47,48,49].”
BackgroundUrani, A., Roman, F. J., Phan, V. L., Su, T., & Maurice, T. (2001) · PubMed · Cited by 181
Sigma-1 receptor knockout mice display a depressive-like phenotype
Sabino, V., Cottone, P., Parylak, S. L., Steardo, L., & Zorrilla, E. P. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.036 · Cited by 163 · cited 1×
“Earlier studies also demonstrate that s1 receptor agonists can modulate the activities of neurotransmitter systems, signaling pathways and brain regions implicated in the pathophysiology of depression [10] and that s1 receptor knockout mice exhibit a depressive-like phenotype [16].”
BackgroundDelayed pharmacological effects of antidepressants
Frazer, A., & Benmansour, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001015 · Cited by 160 · cited 3×
“Dextromethorphan significantly reduced immobility time (Figure 1C; F[4,50] = 6.”
BackgroundNguyen, E. C., McCracken, K. A., Liu, Y., Pouw, B., & Matsumoto, R. R. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.016 · Cited by 146
Self-citationRole of Sigma-1 Receptor C-terminal Segment in Inositol 1,4,5-Trisphosphate Receptor Activation
Wu, Z., & Bowen, W. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802099200 · Cited by 136
Sigma receptors: Potential targets for a new class of antidepressant drug
Fishback, J. A., Robson, M. J., Xu, Y.-T., & Matsumoto, R. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.003 · Cited by 125 · cited 6×
“Dextromethorphan also has higher affinity than ketamine for serotonin transporters (SERT) [9] and several other protein targets, including sigma-1 (s1) receptors [5,9] which have been proposed as therapeutic targets for antidepressant drugs [10].”
BackgroundInfluentialSelf-citationMatsuno, K., Kobayashi, T., Tanaka, M. K., & Mita, S. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00497-9 · Cited by 124
Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., & Sellers, E. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269521 · Cited by 122 · cited 3×
“blocks the CYP2D6 metabolism of dextromethorphan [12], potentiated the antidepressant-like effect of dextromethorphan (10 mg/kg) (Figure 4A).”
BackgroundRobson, M. J., Elliott, M., Seminerio, M. J., & Matsumoto, R. R. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.002 · Cited by 109
Self-citationWerling, L. L., Keller, A. B., Frank, J. G., & Nuwayhid, S. J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.013 · Cited by 107 · cited 8×
“Dextromethorphan also has higher affinity than ketamine for serotonin transporters (SERT) [9] and several other protein targets, including sigma-1 (s1) receptors [5,9] which have been proposed as therapeutic targets for antidepressant drugs [10].”
BackgroundInfluentialUkai, M., Maeda, H., Nanya, Y., Kameyama, T., & Matsuno, K. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00093-8 · Cited by 94 · cited 2×
“An involvement of s1 receptors in the antidepressant-like effects of dextromethorphan is consistent with earlier reports that selective s1 receptor agonists can on their own reduce immobility time in the forced swim test [17,20,21,32] and produce antidepressant-like effects in other animal models such as the tail susp…”
BackgroundHayashi, T., & Su, T.-P. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.1.45 · Cited by 91 · cited 1×
“Compared to existing medications, s1 receptor agonists may facilitate a more rapid onset of antidepressant efficacy [23].”
BackgroundDextromethorphan as a Potential Neuroprotective Agent With Unique Mechanisms of Action
Werling, L. L., Lauterbach, E. C., & Calef, U. (2007) · The Neurologist · doi:10.1097/nrl.0b013e3180f60bd8 · Cited by 87 · cited 2×
“Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of pseudobulbar affect and is thought to produce part of its therapeutic effects through s1 receptors [13].”
BackgroundStanton, T., Watson, C. B., Cusack, B. M., & Richelson, E. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90211-e · Cited by 84 · cited 1×
“This is consistent with the wider range of protein targets through which imipramine, but not dextromethorphan, interacts, which include: serotonin 5-HT2, muscarinic, and histamine H1 receptors [9,45,46,47,48,49].”
BackgroundModulation of serotonergic neurotransmission by short‐ and long‐term treatments with sigma ligands
Bermack, J. E., & Debonnel, G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704294 · Cited by 83 · cited 2×
“Consistent with this, s1 receptor agonists such as (+)pentazocine and SA 4503 can enhance serotonergic neuronal firing in the dorsal raphe nucleus after only two days of treatment, compared to the two weeks of treatment that is typically required of conventional antidepressant drugs [24,25].”
BackgroundCobos, E. J., Baeyens, J. M., & Pozo, E. D. (2005) · Synapse · doi:10.1002/syn.20103 · Cited by 71
Clinical Trials with Sigma Ligands
Volz, H., & Stoll, K.-D. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832680 · Cited by 69 · cited 2×
“The potential clinical relevance of these observations is further supported by reports that s1 receptor agonists produce antidepressant effects in experimental animals and humans [17,18,19,20,21,22].”
BackgroundChou, Y., Liao, J., Chang, W.-Y., Lin, M.-F., & Chen, C. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01125-7 · Cited by 66 · cited 2×
“This activity may convey additional therapeutic advantages over ketamine under clinically relevant conditions since compared to ketamine which has micromolar affinity for s1 receptors [26], dextromethorphan exhibits nanomolar binding affinity for these receptors [9,27,28].”
BackgroundYamamoto, H., Miura, R., Yamamoto, T., Shinohara, K., Watanabe, M., Okuyama, S., Nakazato, A., & Nukada, T. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00084-8 · Cited by 65 · cited 2×
“The second s1 receptor antagonist BD1047 alone displayed no significant effects in the forced swim test (F[3,36] = 2.”
BackgroundPotential antidepressant activity of sigma ligands.
Skuza, G. (2003) · PubMed · Cited by 60
Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice
Wang, J., Mack, A. L., Coop, A., & Matsumoto, R. R. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.007 · Cited by 58
Self-citationLucas, G., Rymar, V. V., Sadikot, A. F., & Debonnel, G. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008547 · Cited by 54 · cited 2×
“Consistent with this, s1 receptor agonists such as (+)pentazocine and SA 4503 can enhance serotonergic neuronal firing in the dorsal raphe nucleus after only two days of treatment, compared to the two weeks of treatment that is typically required of conventional antidepressant drugs [24,25].”
BackgroundLauterbach, E. C. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.012 · Cited by 54 · cited 5×
“In the locomotor studies, BD1047 significantly decreased the effects of dextromethorphan (F[5,61] = 6.”
BackgroundResultInfluentialA potential antidepressant activity of SA4503, a selective σ1 receptor agonist
Skuza, G., & Rogóż, Z. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200211000-00003 · Cited by 37 · cited 2×
“An involvement of s1 receptors in the antidepressant-like effects of dextromethorphan is consistent with earlier reports that selective s1 receptor agonists can on their own reduce immobility time in the forced swim test [17,20,21,32] and produce antidepressant-like effects in other animal models such as the tail susp…”
BackgroundRunyon, S. P., Savage, J. E., Taroua, M., Roth, B. L., Glennon, R. A., & Westkaemper, R. B. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00023-3 · Cited by 19 · cited 1×
“3–20 nM) [40,41,42,43], and s1 receptors (343 nM) [44].”
Nam, Y., Shin, E., Yang, B.-K., Bach, J., Jeong, J. H., Chung, Y. H., Park, E. S., Li, Z., Kim, K.-W., Kwon, Y., et al. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.01.025 · Cited by 17 · cited 3×
“In the locomotor studies, BD1047 produced an effect that significantly differed from saline injections (F[3,34] = 6.”
BackgroundBermack, J. E., Lavoie, N., Dryver, E. T., & Debonnel, G. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002760 · Cited by 16 · cited 1×
“An involvement of s1 receptors in the antidepressant-like effects of dextromethorphan is consistent with earlier reports that selective s1 receptor agonists can on their own reduce immobility time in the forced swim test [17,20,21,32] and produce antidepressant-like effects in other animal models such as the tail susp…”
BackgroundA 96-well filtration method for radioligand binding analysis of σ receptor ligands
Fishback, J. A., Rosen, A., Bhat, R., McCurdy, C., & Matsumoto, R. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.07.023 · Cited by 9 · cited 4×
“This activity may convey additional therapeutic advantages over ketamine under clinically relevant conditions since compared to ketamine which has micromolar affinity for s1 receptors [26], dextromethorphan exhibits nanomolar binding affinity for these receptors [9,27,28].”
BackgroundMethodInfluentialSelf-citation
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Taylor, C. P., Traynelis, S. F., Siffert, J., Pope, L. E., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.010 · Cited by 186
“In the presence of 400 nM DM, radioligand binding of the high-affinity Sig1-R agonist [(3)H](+)pentazocine occurred with reductions in both Kd and Bmax, suggesting complex interactions with Sig1-Rs which may involve competitive as well as non-competitive binding (Nguyen et al., 2014).”
BackgroundMethodInfluentialSelf-citationGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“At the same timepoint, the mice showed behavioral improvement in the FST.”
BackgroundInfluential
Metadata
- Authors
- Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R.
- Affiliations
- West Virginia University (US)
- Corresponding author
- Matsumoto, Rae R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-28
- Volume
- 9
- Issue
- 2
- Pages
- e89985
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3938562
- OpenAlex
- W2122215517
- Cited by
- 99
- References
- 50
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 4 · 2021: 8 · 2020: 12 · 2019: 8 · 2018: 5 · 2017: 11 · 2016: 8 · 2015: 7 · 2014: 2
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Research Repository @ WVU (West Virginia University) (submittedVersion, cc-by)
- Touro Scholar (Touro College) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- West Virginia University
- Avanir Pharmaceuticals
- National Institutes of Health
- National Institute on Drug Abuse (DA013978, R01DA013583, DA013583, R01DA013978)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- dextromethorphan, sigma-1 receptor, antidepressant-like effects, rapid-acting antidepressants, sigma-1 receptor antagonists, BD1047, quinidine, CYP2D6 inhibition, forced swim test, NMDA receptor, ketamine
- MeSH terms
- Sigma-1 Receptor, Adrenergic alpha-Antagonists, Animals, Antidepressive Agents, Behavior, Animal, Cytochrome P-450 Enzyme System, Dextromethorphan, Dose-Response Relationship, Drug, Ethylenediamines, Ketamine, Kinetics, Male, Piperazines, Protein Binding, Quinidine, Swimming, Receptors, N-Methyl-D-Aspartate, Receptors, sigma, Excitatory Amino Acid Antagonists, Mice, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.